{"name":"EndoCeutics Inc.","slug":"endoceutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"DHEA (0.25%)","genericName":"DHEA (0.25%)","slug":"dhea-0-25","indication":"Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women","status":"phase_3"},{"name":"DHEA (0.5%)","genericName":"DHEA (0.5%)","slug":"dhea-0-5","indication":"Moderate to severe dyspareunia due to menopause-related vaginal atrophy","status":"phase_3"},{"name":"DHEA and Acolbifene","genericName":"DHEA and Acolbifene","slug":"dhea-and-acolbifene","indication":"Moderate to severe vasomotor symptoms associated with menopause","status":"phase_3"},{"name":"Prasterone (DHEA)","genericName":"Prasterone (DHEA)","slug":"prasterone-dhea","indication":"Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM) in postmenopausal women","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DHEA (1.0%)","genericName":"DHEA (1.0%)","slug":"dhea-1-0","indication":"Moderate to severe dyspareunia (painful intercourse) due to menopause","status":"phase_3"}]}],"pipeline":[{"name":"DHEA (0.25%)","genericName":"DHEA (0.25%)","slug":"dhea-0-25","phase":"phase_3","mechanism":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women.","indications":["Moderate to severe dyspareunia due to vaginal atrophy in postmenopausal women","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA (0.5%)","genericName":"DHEA (0.5%)","slug":"dhea-0-5","phase":"phase_3","mechanism":"DHEA (dehydroepiandrosterone) is a prohormone that is converted to testosterone and estrogen in peripheral tissues, restoring hormone levels in postmenopausal women.","indications":["Moderate to severe dyspareunia due to menopause-related vaginal atrophy","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA (1.0%)","genericName":"DHEA (1.0%)","slug":"dhea-1-0","phase":"phase_3","mechanism":"DHEA is a steroid hormone precursor that acts as a prohormone, being converted in peripheral tissues to testosterone and estrogen to restore hormonal balance.","indications":["Moderate to severe dyspareunia (painful intercourse) due to menopause","Vaginal atrophy and related menopausal symptoms"],"catalyst":""},{"name":"DHEA and Acolbifene","genericName":"DHEA and Acolbifene","slug":"dhea-and-acolbifene","phase":"phase_3","mechanism":"DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure.","indications":["Moderate to severe vasomotor symptoms associated with menopause","Vaginal atrophy and genitourinary syndrome of menopause"],"catalyst":""},{"name":"Prasterone (DHEA)","genericName":"Prasterone (DHEA)","slug":"prasterone-dhea","phase":"phase_3","mechanism":"Prasterone (DHEA) is a steroid hormone precursor that acts as a substrate for the synthesis of estrogen and androgen, restoring hormonal balance in postmenopausal women.","indications":["Moderate to severe dyspareunia due to genitourinary syndrome of menopause (GSM) in postmenopausal women","Vaginal atrophy and related menopausal symptoms"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPMzhJTWttekpNNklGbjhuTXVURTl6d3k5OE0xbFRWSDN5NmF5NFBxMzBXZklyWVp2Mm1Xa2R4OWcyaVhZcXo1LTE3cFNLMjdQQ1VDckN6eTlfRko1Nk9ONzg5LUhuS3RqbHMwSTFOSTBRN0wwcXJiZ0pubUcxcVVqdmtHZEI3cU8yMEF4UlVLX1k1SDQ4THVCZGFrUHQ4VDdOaGI2QjVCWlBEcDJSZzQzOGNTZDJaeGh3QU9aZHFIc0ItNy1UNXVsSUtFb0FNcF9CUFVKZklyQQ?oc=5","date":"2026-02-07","type":"deal","source":"lupin.com","summary":"Lupin Pharma Canada Announces Partnership with Endoceutics for the commercialization of Intrarosa® - lupin.com","headline":"Lupin Pharma Canada Announces Partnership with Endoceutics for the commercialization of Intrarosa®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOTGduSnJSWmZ5Y0plZkhydUtKNXhIRGNHc2RYWjMxdlpmVU5XVmpBUDJPdEsyMEg3bXFGWjdObFE0X3Byc1hVaTlKZ2NKV1AzRWhwem5WTnFlWHNrMlRsS2tTNzdjT1ZUMnJmUmkyVWlndkpSTWdMemdpdEc4NURTazVuSWJ2STVxTG5jWG5JcFpQY1UyZk5pbUl2bmFPLVhLS2NYWTA0ZUplVzVtcUplUVA1T29tdGpLSTNIb1ZqbXVGSVNmem4yRG5HZ0JpcXpGWngzMGoxNm5NcDMySUVieS0yTWp1VHFhQjRHVzdXSkl4SVoxdlQ0S2VENTVGV29LSDhERU1qLUUtRmlzRW9TZlZ6ZDRwQlh3YVAzSEVRVkVjV2c0U2F4UnpnWjBKYUlXYWx3bTkzX0t2bXJ3cU0xX2Z3?oc=5","date":"2024-06-19","type":"pipeline","source":"McMillan LLP","summary":"Corporate Restructuring Meets Intellectual Property: Quebec Superior Court Overturns Disclaimer Notice and Issues the First Canadian Interpretation of Usage Rights under the CCAA - McMillan LLP","headline":"Corporate Restructuring Meets Intellectual Property: Quebec Superior Court Overturns Disclaimer Notice and Issues the Fi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQcnJLSWl2bkdwUGJYOUNRQXYxMkpHaXdONC1qZGZDMXJPSzdaZUE4SkhmVXYtYWFlVGoydE42ZksxcGFON0Q5VzFhQ21FaUVOSkJFZEdvLWcyUnFWdDRWX2FTYU5GZ2IzRlcxd3UtSnpqdFV6LWNQWnpUQ0JvY0VFSlE0elRSa2VFQUoyelJmOWo0MWx3b1BteGFGT2tRMWc?oc=5","date":"2023-06-09","type":"deal","source":"Pharmaceutical Business review -","summary":"Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug - Pharmaceutical Business review -","headline":"Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug - Pharmaceutical Business review -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNX1dQdjMzOFFpMTJMS25iaUdBemhwV2VnRU1pLXdjNGNvY3A4YlBvcE1zS1FnbnJLMXFqX3czNHJwUXdhNjNZNzUwc2hMVTYtZDU1YkRDRVJid2JXMEk2NlpsbFhwUXVOMUs2V2hNRXNSajJ5b0ZSd3hCNGh5S0xaME16MVR1b1BRRUh3R0NTN25NZVZPaU5DWWNEcG1VZkozckNqZjN30gGsAUFVX3lxTFBaeUVOcTAwYk14ZFJleGxMNlRlNU5iQVZWSjhQNFNkUHNsaFNtVGctcHZFOFJ0OHdyZW45OEx1bGZLc2p5T0c3clZlc3h4MElOclAtLXVnalFwdnp5QnFIaTFTaGJoc2trdTBXa0VLLVBFLVpFYV9mVlIwWXB1T0otcEpwazZvZWNZMkFoWnhIN0hCNFNDR2tpZ2lhNzJFVjFQTkExbW5iWkFQVEQ?oc=5","date":"2023-06-09","type":"deal","source":"Indian Pharma Post","summary":"Cosette Pharmaceuticals acquires Intrarosa from Endoceutics - Indian Pharma Post","headline":"Cosette Pharmaceuticals acquires Intrarosa from Endoceutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSUZkWXJDdTlwNnk5MWZqWFVzUklBU3NNSUV2YzNuSVlPcHc1RUZha0JUdU1SUEk4NGZwcHVpR2lTVWJwR1ROb1lObk4xSV9TNUwyMF9IYXhEaXJISXpXUXgtMm9XU0tJSGQ1YVlMOXR6a2NVSnRDOWRjTTBmTW1WTFFJNTVEaFVWcF8zTi1uUG1RVXhOTXZUemIyNXJhQWZNOXpONkNpaXhUQllqcWdwVVJYcDV3c3pjaDF2ejNn?oc=5","date":"2023-06-08","type":"deal","source":"businesswire.com","summary":"Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc. - businesswire.com","headline":"Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOVdUbXFIaUxZcFQ1MW50RmwyMktLU0VDbDFidWZyWWhvbklzY1ZWc2tweVl5OHVGNk5mTzlZeUZkeUREaG5SOExla0lRZ0h3bjYtTzkzT0xkWHUzencwWTdhMzhPaVhnY1lPZmhQMkpvdU40STRUSWpJU0IwSlN5S2ttZ0tDUTBrR0szY2RJZ052QQ?oc=5","date":"2023-06-08","type":"deal","source":"BioSpace","summary":"Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc. - BioSpace","headline":"Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxORXJFQnA2bllVNmVNRWJOVXF0UW1ua0VGM3UyR2JWLW51ZlE0UlhoeFVSMWlBZGxqSkhoRDA3aGtzV1NWYVFRLXZHUVVrRGJOX1Vidk9xc1QyQy1fd3RxRGJMcFI4azJEYmhPX09adENCOXZTQ1Vza1hIWmk4Ukhaekw0ZWQyeXdKem9uNEp0ckhCWk53QmN4aGdIZjJNUHkzN05jQ192aVFYMlhsS3dudkROQUs2VjJsQnhTa3dITEU0aTZSSWVOZHhXZ3ctTTEyZUEtYkZkRFZZU3YyY2RNcmN3MmpqLWZSazh0TnpUVWRQMzRLbWotTHhDQmM4dWxYT3BBQ0hBaURodU0zSUMyUnJRbXBFdFRtbHc2cXBsdm1IZU55NVdWeUFMNmt2aUM3YVhVNVp3TG95NVl5MVVyaGZ1ZkdnWk0?oc=5","date":"2023-01-25","type":"pipeline","source":"Newswire Canada","summary":"Lupin Pharma Canada announces the availability of Intrarosa® (prasterone vaginal ovules), a new treatment option in Canada for women with postmenopausal vulvovaginal atrophy - Newswire Canada","headline":"Lupin Pharma Canada announces the availability of Intrarosa® (prasterone vaginal ovules), a new treatment option in Cana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNYkJCSjhpamtIM0k0aU96ZXNQVVFkNW9PZ29JUW9vSXI4Y3kzZHZUYVBVTHd2S1dRdUUxa0txbUwzdXNOWHJWZm9hNExTZy1FQUQ5aGQtNFgtT0ltUTJzSjdNSkJFdS1jYVNtdk9GdTVKSHFkQ09scUZ1WDdLT29ybWtBbXlXRTh3Nm9sbEhKZFdsTUN6TTg3ZW03cFdvSndfOGxkeHRNRHhXcXFsOWpWTFVzbFRfcTl3Ykc5dmV1bU90ZDFFamlHMnM2NXViMDVRS2hyRWprVHA?oc=5","date":"2018-05-20","type":"deal","source":"PR Newswire","summary":"Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region - PR Newswire","headline":"Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPTHdZOUV5VFBTTC01NHlwOGIwQ2dKYmNvVnQ3aEM3T1UwWlFZQW1YSTZqTnJ6OUhSZzZxUHdPcnBJU1BXR1RaUDFkSkM3YnpNOEFOUlBDdUY3N0hLT1RSWTRpWkxna2JITTdfelBUMGotX210ZVI1VklEckhPTGFCVVVzRWdCRDZCLTZqQlZVeGtQeC1GVjNzeWpzSl84SHdlWFhpSDN4azlaZ3dK?oc=5","date":"2010-05-05","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"Bayer Schering Pharma and EndoCeutics enter into a global agreement - Hospital Pharmacy Europe","headline":"Bayer Schering Pharma and EndoCeutics enter into a global agreement","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}